G
Gary M. Clark
Researcher at OSI Pharmaceuticals
Publications - 35
Citations - 15648
Gary M. Clark is an academic researcher from OSI Pharmaceuticals. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 28, co-authored 35 publications receiving 14905 citations. Previous affiliations of Gary M. Clark include University of Texas Health Science Center at San Antonio & Houston Methodist Hospital.
Papers
More filters
Journal ArticleDOI
Erlotinib in previously treated non-small-cell lung cancer.
Frances A. Shepherd,José Rodrigues Pereira,Tudor Ciuleanu,Eng Huat Tan,Vera Hirsh,Sumitra Thongprasert,Daniel Campos,Savitree Maoleekoonpiroj,Michael Smylie,Renato G. Martins,Maximiliano Van Kooten,Mircea Dediu,B. Findlay,Dongsheng Tu,Dianne Johnston,Andrea Bezjak,Gary M. Clark,Pedro Santabárbara,Lesley Seymour +18 more
TL;DR: Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
Journal ArticleDOI
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
TL;DR: In this article, the authors present guidelines for the reporting of tumor marker studies, which encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
Journal Article
Reporting recommendations for tumor marker prognostic studies (remark).
TL;DR: These guidelines are designed to encourage transparent and complete reporting of tumor marker studies so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
Journal ArticleDOI
REporting recommendations for tumour MARKer prognostic studies (REMARK)
Lisa M. McShane,Douglas G. Altman,Willi Sauerbrei,Sheila E. Taube,Massimo Gion,Gary M. Clark +5 more
TL;DR: The goal of these guidelines is to encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
Journal ArticleDOI
Reporting recommendations for tumor marker prognostic studies.
Lisa M. McShane,Douglas G. Altman,Willi Sauerbrei,Sheila E. Taube,Massimo Gion,Gary M. Clark +5 more
TL;DR: This paper presents the results of a two-month study conducted in partnership with the University of Oxford and the NCI-EORTC Working Group on Cancer Diagnostics on biomarkers used in cancer diagnosis and prognosis.